Chemotherapy and vitamin D supplement use are determinants of serum 25-hydroxyvitamin D levels during the first six months after colorectal cancer diagnosis

Evertine Wesselink*, Martijn J.L. Bours, Johannes H.W. de Wilt, Michiel Aquarius, Stephanie O. Breukink, Bibi Hansson, Eric T.P. Keulen, Dieuwertje E. Kok, Jody van den Ouweland, Eline H. van Roekel, Merel Snellen, Renate Winkels, Renger F. Witkamp, Moniek van Zutphen, Matty P. Weijenberg, Ellen Kampman, Fränzel J.B. van Duijnhoven

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Vitamin D metabolites, including 25-hydroxyvitamin D3 (25(OH)D3), may inhibit colorectal cancer (CRC) progression. Here we investigated cross-sectional and longitudinal associations of demographic, lifestyle and clinical characteristics with 25(OH)D3 serum concentrations in CRC patients at diagnosis and six months later. In 1201 newly-diagnosed stage I-III CRC patients, 25(OH)D3 levels were analysed twice. Multivariable linear regression was used to assess demographic, lifestyle and clinical determinants of 25(OH)D3 levels at diagnosis and six months later. Linear mixed models were used to assess characteristics associated with changes in 25(OH)D3 levels over time. Results of our study showed that vitamin D intake from diet or supplements, use of calcium supplements, BMI and disease stage were associated with 25(OH)D3 levels at both time points. Six months after diagnosis, gender and having received chemo- and/or radiotherapy were also associated with 25(OH)D3 levels. A stronger decrease in 25(OH)D3 levels was observed in patients who underwent chemotherapy, compared to surgery only (β-6.9 nmol/L 95 %CI -9.8; -4.0). Levels of 25(OH)D3 levels increased in patients using vitamin D supplements compared to non-users (β 4.0 nmol/L 95 %CI 1.2; 6.8). In conclusion, vitamin D supplement use and treatment appear to be important determinants of 25(OH)D3 levels during the first six months after CRC diagnosis, although the difference in 25(OH)D3 levels was minor. ClinicalTrials.gov Identifier: NCT03191110

Original languageEnglish
Article number105577
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume199
DOIs
Publication statusPublished - 1 May 2020

Fingerprint

Chemotherapy
Vitamin D
Colorectal Neoplasms
Drug Therapy
Serum
Life Style
Linear Models
Demography
Calcifediol
Radiotherapy
Nutrition
Metabolites
Linear regression
Surgery
Diet
Calcium
25-hydroxyvitamin D
Therapeutics

Keywords

  • Changes over time
  • Colorectal cancer
  • Lifestyle and clinical determinants
  • Patients
  • serum 25(OH)D
  • Vitamin D

Cite this

Wesselink, Evertine ; Bours, Martijn J.L. ; de Wilt, Johannes H.W. ; Aquarius, Michiel ; Breukink, Stephanie O. ; Hansson, Bibi ; Keulen, Eric T.P. ; Kok, Dieuwertje E. ; van den Ouweland, Jody ; van Roekel, Eline H. ; Snellen, Merel ; Winkels, Renate ; Witkamp, Renger F. ; van Zutphen, Moniek ; Weijenberg, Matty P. ; Kampman, Ellen ; van Duijnhoven, Fränzel J.B. / Chemotherapy and vitamin D supplement use are determinants of serum 25-hydroxyvitamin D levels during the first six months after colorectal cancer diagnosis. In: Journal of Steroid Biochemistry and Molecular Biology. 2020 ; Vol. 199.
@article{33cbf9ffb83e4fbc8369fa175295b037,
title = "Chemotherapy and vitamin D supplement use are determinants of serum 25-hydroxyvitamin D levels during the first six months after colorectal cancer diagnosis",
abstract = "Vitamin D metabolites, including 25-hydroxyvitamin D3 (25(OH)D3), may inhibit colorectal cancer (CRC) progression. Here we investigated cross-sectional and longitudinal associations of demographic, lifestyle and clinical characteristics with 25(OH)D3 serum concentrations in CRC patients at diagnosis and six months later. In 1201 newly-diagnosed stage I-III CRC patients, 25(OH)D3 levels were analysed twice. Multivariable linear regression was used to assess demographic, lifestyle and clinical determinants of 25(OH)D3 levels at diagnosis and six months later. Linear mixed models were used to assess characteristics associated with changes in 25(OH)D3 levels over time. Results of our study showed that vitamin D intake from diet or supplements, use of calcium supplements, BMI and disease stage were associated with 25(OH)D3 levels at both time points. Six months after diagnosis, gender and having received chemo- and/or radiotherapy were also associated with 25(OH)D3 levels. A stronger decrease in 25(OH)D3 levels was observed in patients who underwent chemotherapy, compared to surgery only (β-6.9 nmol/L 95 {\%}CI -9.8; -4.0). Levels of 25(OH)D3 levels increased in patients using vitamin D supplements compared to non-users (β 4.0 nmol/L 95 {\%}CI 1.2; 6.8). In conclusion, vitamin D supplement use and treatment appear to be important determinants of 25(OH)D3 levels during the first six months after CRC diagnosis, although the difference in 25(OH)D3 levels was minor. ClinicalTrials.gov Identifier: NCT03191110",
keywords = "Changes over time, Colorectal cancer, Lifestyle and clinical determinants, Patients, serum 25(OH)D, Vitamin D",
author = "Evertine Wesselink and Bours, {Martijn J.L.} and {de Wilt}, {Johannes H.W.} and Michiel Aquarius and Breukink, {Stephanie O.} and Bibi Hansson and Keulen, {Eric T.P.} and Kok, {Dieuwertje E.} and {van den Ouweland}, Jody and {van Roekel}, {Eline H.} and Merel Snellen and Renate Winkels and Witkamp, {Renger F.} and {van Zutphen}, Moniek and Weijenberg, {Matty P.} and Ellen Kampman and {van Duijnhoven}, {Fr{\"a}nzel J.B.}",
year = "2020",
month = "5",
day = "1",
doi = "10.1016/j.jsbmb.2020.105577",
language = "English",
volume = "199",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier",

}

Chemotherapy and vitamin D supplement use are determinants of serum 25-hydroxyvitamin D levels during the first six months after colorectal cancer diagnosis. / Wesselink, Evertine; Bours, Martijn J.L.; de Wilt, Johannes H.W.; Aquarius, Michiel; Breukink, Stephanie O.; Hansson, Bibi; Keulen, Eric T.P.; Kok, Dieuwertje E.; van den Ouweland, Jody; van Roekel, Eline H.; Snellen, Merel; Winkels, Renate; Witkamp, Renger F.; van Zutphen, Moniek; Weijenberg, Matty P.; Kampman, Ellen; van Duijnhoven, Fränzel J.B.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 199, 105577, 01.05.2020.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Chemotherapy and vitamin D supplement use are determinants of serum 25-hydroxyvitamin D levels during the first six months after colorectal cancer diagnosis

AU - Wesselink, Evertine

AU - Bours, Martijn J.L.

AU - de Wilt, Johannes H.W.

AU - Aquarius, Michiel

AU - Breukink, Stephanie O.

AU - Hansson, Bibi

AU - Keulen, Eric T.P.

AU - Kok, Dieuwertje E.

AU - van den Ouweland, Jody

AU - van Roekel, Eline H.

AU - Snellen, Merel

AU - Winkels, Renate

AU - Witkamp, Renger F.

AU - van Zutphen, Moniek

AU - Weijenberg, Matty P.

AU - Kampman, Ellen

AU - van Duijnhoven, Fränzel J.B.

PY - 2020/5/1

Y1 - 2020/5/1

N2 - Vitamin D metabolites, including 25-hydroxyvitamin D3 (25(OH)D3), may inhibit colorectal cancer (CRC) progression. Here we investigated cross-sectional and longitudinal associations of demographic, lifestyle and clinical characteristics with 25(OH)D3 serum concentrations in CRC patients at diagnosis and six months later. In 1201 newly-diagnosed stage I-III CRC patients, 25(OH)D3 levels were analysed twice. Multivariable linear regression was used to assess demographic, lifestyle and clinical determinants of 25(OH)D3 levels at diagnosis and six months later. Linear mixed models were used to assess characteristics associated with changes in 25(OH)D3 levels over time. Results of our study showed that vitamin D intake from diet or supplements, use of calcium supplements, BMI and disease stage were associated with 25(OH)D3 levels at both time points. Six months after diagnosis, gender and having received chemo- and/or radiotherapy were also associated with 25(OH)D3 levels. A stronger decrease in 25(OH)D3 levels was observed in patients who underwent chemotherapy, compared to surgery only (β-6.9 nmol/L 95 %CI -9.8; -4.0). Levels of 25(OH)D3 levels increased in patients using vitamin D supplements compared to non-users (β 4.0 nmol/L 95 %CI 1.2; 6.8). In conclusion, vitamin D supplement use and treatment appear to be important determinants of 25(OH)D3 levels during the first six months after CRC diagnosis, although the difference in 25(OH)D3 levels was minor. ClinicalTrials.gov Identifier: NCT03191110

AB - Vitamin D metabolites, including 25-hydroxyvitamin D3 (25(OH)D3), may inhibit colorectal cancer (CRC) progression. Here we investigated cross-sectional and longitudinal associations of demographic, lifestyle and clinical characteristics with 25(OH)D3 serum concentrations in CRC patients at diagnosis and six months later. In 1201 newly-diagnosed stage I-III CRC patients, 25(OH)D3 levels were analysed twice. Multivariable linear regression was used to assess demographic, lifestyle and clinical determinants of 25(OH)D3 levels at diagnosis and six months later. Linear mixed models were used to assess characteristics associated with changes in 25(OH)D3 levels over time. Results of our study showed that vitamin D intake from diet or supplements, use of calcium supplements, BMI and disease stage were associated with 25(OH)D3 levels at both time points. Six months after diagnosis, gender and having received chemo- and/or radiotherapy were also associated with 25(OH)D3 levels. A stronger decrease in 25(OH)D3 levels was observed in patients who underwent chemotherapy, compared to surgery only (β-6.9 nmol/L 95 %CI -9.8; -4.0). Levels of 25(OH)D3 levels increased in patients using vitamin D supplements compared to non-users (β 4.0 nmol/L 95 %CI 1.2; 6.8). In conclusion, vitamin D supplement use and treatment appear to be important determinants of 25(OH)D3 levels during the first six months after CRC diagnosis, although the difference in 25(OH)D3 levels was minor. ClinicalTrials.gov Identifier: NCT03191110

KW - Changes over time

KW - Colorectal cancer

KW - Lifestyle and clinical determinants

KW - Patients

KW - serum 25(OH)D

KW - Vitamin D

U2 - 10.1016/j.jsbmb.2020.105577

DO - 10.1016/j.jsbmb.2020.105577

M3 - Article

VL - 199

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

M1 - 105577

ER -